da Luca Bonadei | Giu 14, 2019 | Pricing
https://www.ilsole24ore.com After the obtaining of Marketing Authorisation by EMA in the early days of June, Bluebird Bio annouces a price for Zynteglo, its gene therapy for the treatment of transfusion-dependent β-thalassemia in patients without donors for...
da Luca Bonadei | Mag 27, 2019 | Pricing
https://www.pharmastar.it FDA has approved Zolgensma, Novartis gene therapy against spinal muscular atrophy type 1, with a price of $2,125 million per patient. The treatment is the most expensive in history but, according to the swiss Company, the lifesaving benefit...
da Luca Bonadei | Mag 22, 2019 | Pricing
https://www.reuters.com Zolgensma, Novartis one-time gene therapy for the treatment of spinal muscular atrophy, is waiting the FDA market authorization within the month. The swiss company’s CEO said that the price for the gene therapy will be far lower than the rumors...
da Luca Bonadei | Gen 26, 2019 | Pricing
“https://www.masslive.com” Facing the cost of gene therapy
da Luca Bonadei | Nov 21, 2018 | Pricing
“https://www.ajmc.com”
da Luca Bonadei | Nov 6, 2018 | Pricing
“https://pharmaphorum.com”